These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24857404)

  • 21. Novel drug design for Chagas disease via targeting Trypanosoma cruzi tubulin: Homology modeling and binding pocket prediction on Trypanosoma cruzi tubulin polymerization inhibition by naphthoquinone derivatives.
    Ogindo CO; Khraiwesh MH; George M; Brandy Y; Brandy N; Gugssa A; Ashraf M; Abbas M; Southerland WM; Lee CM; Bakare O; Fang Y
    Bioorg Med Chem; 2016 Aug; 24(16):3849-55. PubMed ID: 27345756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Approaches for the development of new anti-Trypanosoma cruzi agents.
    Moreira DR; Leite AC; dos Santos RR; Soares MB
    Curr Drug Targets; 2009 Mar; 10(3):212-31. PubMed ID: 19275558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trypanocidal effect of the benzyl ester of N-propyl oxamate: a bi-potential prodrug for the treatment of experimental Chagas disease.
    Wong-Baeza C; Nogueda-Torres B; Serna M; Meza-Toledo S; Baeza I; Wong C
    BMC Pharmacol Toxicol; 2015 Apr; 16():10. PubMed ID: 25896924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of juvenile hormone analogues (JHA) on the development of Trypanosoma cruzi.
    Fichera L; Esteva M; Wimmer Z; Rodriguez JB; Gros EG
    Z Naturforsch C J Biosci; 1995; 50(7-8):578-80. PubMed ID: 7546047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs.
    Vázquez K; Paulino M; Salas CO; Zarate-Ramos JJ; Vera B; Rivera G
    Mini Rev Med Chem; 2017; 17(11):939-946. PubMed ID: 28302040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Nifurtimox, a bright future for treatment of Chagas disease].
    Wolf A; Boulliat C; Coillot C; Rouault M; Gaillard K; Beranger C; Oliver M
    Med Trop (Mars); 2011 Apr; 71(2):131-3. PubMed ID: 21695868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological factors that impinge on Chagas disease drug development.
    Francisco AF; Jayawardhana S; Lewis MD; Taylor MC; Kelly JM
    Parasitology; 2017 Dec; 144(14):1871-1880. PubMed ID: 28831944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A proteomic analysis of the mechanism of action of naphthoimidazoles in Trypanosoma cruzi epimastigotes in vitro.
    Menna-Barreto RF; Beghini DG; Ferreira AT; Pinto AV; De Castro SL; Perales J
    J Proteomics; 2010 Nov; 73(12):2306-15. PubMed ID: 20621210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thioridazine treatment modifies the evolution of Trypanosoma cruzi infection in mice.
    Rivarola HW; Fernández AR; Enders JE; Fretes R; Gea S; Suligoy M; Palma JA; Paglini-Oliva P
    Ann Trop Med Parasitol; 1999 Oct; 93(7):695-702. PubMed ID: 10715697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nifurtimox chemotherapy: collateral effects in treated Trypanosoma cruzi infected patients.
    Murcia L; Carrilero B; Albajar Viñas P; Segovia M
    Rev Esp Quimioter; 2012 Mar; 25(1):74-5. PubMed ID: 22488545
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of Chagas' disease].
    Apt W
    Rev Med Chil; 1985 Feb; 113(2):162-6. PubMed ID: 3936147
    [No Abstract]   [Full Text] [Related]  

  • 32. Trypanocidal activity of extracts and fractions of Bertholletia excelsa.
    Campos FR; Januário AH; Rosas LV; Nascimento SK; Pereira PS; França SC; Cordeiro MS; Toldo MP; Albuquerque S
    Fitoterapia; 2005 Jan; 76(1):26-9. PubMed ID: 15664458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chagas disease drug discovery: toward a new era.
    Chatelain E
    J Biomol Screen; 2015 Jan; 20(1):22-35. PubMed ID: 25245987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenotypic screening approaches for Chagas disease drug discovery.
    Chatelain E; Ioset JR
    Expert Opin Drug Discov; 2018 Feb; 13(2):141-153. PubMed ID: 29235363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trypanocidal activity of 4 isopropyl salicylaldehyde and 4-isopropyl salicylic acid on Trypanosoma cruzi.
    Nogueda-Torres B; Rodríguez-Paez L; Ramírez IB; Ramírez CW
    Rev Latinoam Microbiol; 2001; 43(1):1-6. PubMed ID: 17061565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in Chagas disease drug development: 2009-2010.
    Buckner FS; Navabi N
    Curr Opin Infect Dis; 2010 Dec; 23(6):609-16. PubMed ID: 20885320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi.
    Keenan M; Alexander PW; Diao H; Best WM; Khong A; Kerfoot M; Thompson RC; White KL; Shackleford DM; Ryan E; Gregg AD; Charman SA; von Geldern TW; Scandale I; Chatelain E
    Bioorg Med Chem; 2013 Apr; 21(7):1756-63. PubMed ID: 23462713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cruzi Drugs.
    Urbina JA; McKerrow JH
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7923-4. PubMed ID: 26578701
    [No Abstract]   [Full Text] [Related]  

  • 39. Novel drug discovery for Chagas disease.
    Moraes CB; Franco CH
    Expert Opin Drug Discov; 2016; 11(5):447-55. PubMed ID: 26967915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of drug sensitivities of three strains of Trypanosoma cruzi in inbred A/Jax mice.
    Cover B; Gutteridge WE
    Trans R Soc Trop Med Hyg; 1981; 75(2):274-81. PubMed ID: 6795771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.